Shield Therapeutics plc (LON:STX – Get Free Report) reached a new 52-week low during trading on Monday . The company traded as low as GBX 1.50 ($0.02) and last traded at GBX 1.54 ($0.02), with a volume of 1817725 shares changing hands. The stock had previously closed at GBX 1.50 ($0.02).
Shield Therapeutics Stock Down 4.9 %
The business has a fifty day moving average of GBX 2.88 and a 200 day moving average of GBX 5.20. The firm has a market cap of £11.34 million, a P/E ratio of -12.29 and a beta of 0.84. The company has a quick ratio of 2.16, a current ratio of 2.95 and a debt-to-equity ratio of 21.30.
Shield Therapeutics Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Read More
- Five stocks we like better than Shield Therapeutics
- 3 Small Caps With Big Return Potential
- ASML Fires Warning Shot For Tech Investors
- What Are Growth Stocks and Investing in Them
- Prologis Stock Leading U.S. Logistics Boom
- Basic Materials Stocks Investing
- Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.